• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

临床输血与检验 ›› 2026, Vol. 28 ›› Issue (5): 853-862.DOI: 10.3969/j.issn.1671-2587.2026.05.025

• 综述 • 上一篇    下一篇

血小板ABH抗原的个体表达差异及其功能在输血医学中的研究进展*

操博为, 程红, 李丹丹, 王志成   

  1. 复旦大学附属华山医院输血医学科,上海 200040
  • 收稿日期:2026-09-02 修回日期:2026-09-23 出版日期:2026-10-20 发布日期:2026-11-11
  • 通讯作者: 王志成,主要从事输血医学相关方面的研究,(E-mail)wangzhicheng@huashan.org.cn。
  • 作者简介:操博为,主要从事血小板相关方面的研究,(E-mail)17786358546@163.com。

Advances in Individual Variability in Platelet ABH Antigen Expression and Its Functional Implications for Transfusion Medicine

CAO Bowei, CHENG Hong, LI Dandan, WANG Zhicheng   

  1. Department of Transfusion Medicine, Huashan Hospital, Fudan University, Shanghai 200040
  • Received:2026-09-02 Revised:2026-09-23 Online:2026-10-20 Published:2026-11-11

摘要: 血小板ABH抗原是位于膜糖蛋白和糖鞘脂末端的糖链结构,其形成涉及巨核细胞-血小板轴的内源性糖基化以及血浆ABH活性物质的外源性吸附。GPⅠb-Ⅸ-Ⅴ复合物及整合素等可携带ABH决定簇,A1、A2亚型及高表达表型(high-expresser phenotype, HXP)和低表达表型(low-expresser phenotype, LXP)间存在明显差异。HXP/LXP是在特定检测体系下按血小板ABH抗原相对表达量划分的表达表型,并非新的ABO血型亚型,其分类受检测试剂、流式平台、分析方法和判定阈值影响,目前缺乏统一的跨中心标准。现有功能研究提示,ABO相关糖基化可能影响GPⅠb-Ⅸ-Ⅴ与血管性血友病因子(VWF)的结合动力学,抗-A/B在体外亦可改变血小板聚集、铺展、凝血酶生成和介质释放;这些结果尚不足以建立临床出血或血栓的因果关系。在输血实践中,主要ABO不相合影响输注后血小板回收和计数增量,次要ABO不相合可因被动输入抗体引起少见但严重的溶血,双向ABO不相合则兼具两类风险。在库存允许的情况下,可优先考虑ABO同型血小板;A2或LXP血小板在特定主要ABO不相合情境中具有一定价值,但尚缺乏标准化筛查体系和前瞻性临床结局证据,不足以支持常规推荐。

关键词: ABH抗原, 血小板, ABO血型系统, 血小板输注, 血管性血友病因子

Abstract: Platelet ABH antigens are terminal glycan structures carried by membrane glycoproteins and glycosphingolipids. Their expression reflects endogenous glycosylation along the megakaryocyte-platelet axis and adsorption of ABH-active substances from plasma. The GPⅠb-Ⅸ-Ⅴ complex and integrins can carry ABH determinants, with substantial variation among the A1 and A2 subgroups and the high-expresser phenotype (HXP) and low-expresser phenotype (LXP). HXP and LXP are assay-dependent expression phenotypes rather than new ABO subgroups; their classification varies with reagents, flow-cytometry platforms, analytical methods, and thresholds, and no cross-center standard is currently available. Available functional studies suggest that ABO-related glycosylation may affect the binding kinetics between GPⅠb-Ⅸ-Ⅴ and von Willebrand factor (VWF), Furthermore, anti-A/B antibodies have been shown to alter platelet aggregation, spreading, thrombin generation, and mediator release in vitro. However, these findings are currently insufficient to establish a causal relationship with clinical bleeding or thrombosis events. In transfusion practice, major ABO incompatibility concerns post-transfusion platelet recovery and count increments, minor incompatibility can cause rare but severe hemolysis through passively transfused antibodies, and bidirectional incompatibility combines both risks. When inventory permits, ABO-identical platelets may be considered preferentially. Platelets with A2 or LXP phenotype may be valuable in selected major ABO-incompatible settings, but standardized screening and prospective clinical-outcome evidence remain insufficient for routine recommendation.

Key words: ABH antigens, Platelets, ABO blood-group system, Platelet transfusion, Von Willebrand factor

中图分类号: